Passage Bio (PASG) Osake Kurssi

Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 20 full-time employees. The company went IPO on 2020-02-28. The firm is focused on developing transformative therapies for rare, monogenic central nervous system (CNS). The firm is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The firm's products pipeline includes PBGM01 for the treatment of gangliosidosis (GM1), PBFT02 for the treatment of frontotemporal dementia (FTD), and PBKR03 for the treatment of Krabbe disease. The Company’s products PBGM01, utilizes an AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (beta-gal), PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN), and PBKR03, utilizes an AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC).